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Summary 
Background: Whether a relationship between atherosclerosis and subsequent venous 
thromboembolism (VTE) exists is controversial.  
Objective: To investigate the association between carotid atherosclerosis and VTE using 
repeated measurements of intima media thickness (IMT) and total plaque area (TPA) in 
participants recruited from the general population. 
Methods: Participants were recruited from the fourth (1994-1995), fifth (2001-2002) and 
sixth (2007-2008) surveys of the Tromsø study. In total, 10426 participants attended, for 
whom measurements of carotid IMT and TPA and potential confounders were updated at 
each available survey. Time-varying Cox-regression models were used to calculate 
hazard ratios (HR) of VTE across various levels of IMT and TPA adjusted for age, sex 
and body mass index.  
Results: There were 368 incident VTE events during a median follow-up of 10.8 years. 
Participants with increasing IMT were on average older and had a less favorable 
cardiovascular risk profile. There was no association between tertiles of increasing TPA 
and risk of VTE in the time-varying model, and increasing IMT was not associated with 
increased risk of VTE (HR 0.96, 95% CI 0.86-1.07). Neither plaque formation nor plaque 
progression was associated with risk of VTE (HR 1.00, 95% CI 0.98-1.02 and HR 0.96, 
95% CI 0.84-1.11, respectively). 
Conclusion: Carotid IMT and TPA was not associated with increased risk of VTE in 
time-varying analyses. Furthermore, there was no association between plaque initiation or 
plaque progression and subsequent VTE. 
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• The relationship between atherosclerosis and venous thromboembolism (VTE) is 
controversial 
• In total, 10426 participants recruited from the general population were included 
• Carotid intima media thickness and total plaque area was not associated with VTE 













Although medical textbooks consider venous thromboembolism (VTE)  and arterial 
cardiovascular disease as different disease entities [1], Virchow’s triad (1856) postulates 
that the pathophysiology of thrombosis, either venous or arterial, is an interplay between 
1) stasis of the blood, 2) hypercoagulability, and 3) vessel wall injury [2]. The vascular 
component of Virchow’s triad has been much less studied in the etiology of VTE as 
compared with arterial cardiovascular disease where vessel wall injury is an established 
precursor of disease.  
Interestingly, recent studies have shown that arterial cardiovascular diseases, such 
as myocardial infarction and ischemic stroke, are associated with an increased risk of 
VTE [3-5]. In addition, in a landmark study from 2003, Prandoni et al. reported that 
atherosclerosis, measured by total plaque area [TPA], was twice as prevalent in patients 
with unprovoked venous thrombosis as in age and sex matched controls [6]. These 
findings suggested that atherosclerosis could be a shared risk factor for arterial 
cardiovascular disease and VTE. Although the association between atherosclerosis and 
arterial cardiovascular disease is well established [7-9], the association between 
atherosclerosis and VTE remains controversial. For instance, case-control studies are not 
designed to reveal the direction of the association and does not enable interpretations on 
causality due to the undetermined temporal sequence between exposure and outcome. 
Furthermore, the association between atherosclerosis and VTE might be explained by 
presence of confounding risk factors, such as increasing age and obesity [10].  
Previous cohort studies did not show any association between atherosclerosis and 
subsequent VTE [11-13]. However, these cohorts were based on a single measurement of 
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TPA and carotid intima media thickness (IMT) obtained at the beginning of a follow-up 
period that lasted for more than 10 years. Because atherosclerosis may develop over time, 
a long follow-up with several years between the baseline measurement and the event 
could introduce regression dilution bias and thereby lead to underestimation of the true 
association [14, 15]. Therefore, a small effect of atherosclerosis on VTE risk could be 
masked in traditional cohort studies with single measurements and long-term follow-up. 
The potential problem of regression dilution could be overcome by utilizing repeated 
assessments of the atherosclerosis status within the same individuals during follow-up. 
This will provide a more accurate estimation of the risk status at the time before the 
outcome occurs.  
 We therefore aimed to investigate the association between the presence, formation 
and progression of carotid atherosclerosis and VTE using a large prospective cohort with 





Participants were recruited from the fourth, fifth and sixth surveys of The Tromsø Study, 
conducted in 1994-95, 2001-02 and 2007-08, respectively. In the fourth study, all 
inhabitants aged 55-74 years and a random 5-10% sample in the other age groups >24 
years, were invited to a second, more extensive examination, including ultrasound 
scanning of the carotid artery [16]. Subjects who attended the second visit of Tromsø 4, 
in addition to random samples within different age-groups, were eligible for the second 
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visit of Tromsø 5 and in Tromsø 6. A detailed description of the Tromsø Study has been 
published elsewhere [17]. Participants with a previous history of VTE were excluded. In 
addition, participants attending the ultrasound examination, but with missing information 
on the measures of carotid atherosclerosis, were excluded. In total, 10426 participants 
attended an ultrasound examination of the right carotid artery in Tromsø 4, 5 and/or 6 
(Figure 1). The study was approved by the regional committee for research ethics in 
North Norway, and all participants gave their informed, written consent. 
 
Atherosclerotic risk factors and assessment of atherosclerosis 
Information on atherosclerotic risk factors was collected by physical examination, blood 
samples and self-administered questionnaires, and repeated at each survey. Height, 
weight, blood pressure and non-fasting serum lipids were measured as previously 
described in detail [18]. Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in meters (kg/m2). Questionnaires were used to obtain 
information on use of lipid-lowering drugs, current smoking, diabetes mellitus, physical 
activity and education.  
Ultrasound examination of the right carotid artery was performed for assessment 
of TPA and IMT. A thorough description of the ultrasonographic examination has been 
published previously [16, 19-21]. In brief , high-resolution B-mode ultrasonography of 
the right carotid artery was performed by experienced examiners, with the use of an 
ultrasound scanner (Acuson Xp10 128 ART equipped with a 7.5 MHz linear-array 
transducer in Tromsø 4 and 5; and a GE Vivid 7 with a linear 12 MHz transducer in 
Tromsø 6). The right carotid artery was scanned longitudinally from the level of the 
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clavicle, through the carotid bulb (bifurcation segment) and the proximal internal carotid 
segment (ICA) as far downstream as possible. A plaque was defined as a localized 
protrusion of the vessel wall into the lumen of at least 50% compared to the adjacent 
IMT. Still images were reported for each plaque and digitized using the Matrox Meteor II 
frame grabber card and Matrox Intellicam. With the use of Adobe Photoshop 7.0, 
measurements of plaque area were made by outlining the perimeter of the plaque, and the 
plaque area was calculated as pixel values. For the resolution used in the present study, a 
plaque area of 167 pixels corresponded to 1 mm2. In each subject, a maximum of six 
plaques were registered in the near and far walls of the distal part of the common carotid 
artery (CCA), bifurcation, and ICA, respectively. TPA was calculated as the sum of all 
plaques. IMT was defined as the average of the mean IMT values of the near and far wall 
of the CCA and far wall of the bifurcation. To minimize variability in IMT during the 
cardiac cycle, image capturing was standardized by recording images at the top of the R 
wave in an ECG signal. Plaque initiation was defined as development of new plaques at 
follow-up in vessels without plaques at the previous examination, and plaque progression 
as the difference in TPA two measurements. Participants with negative progression were 
included in the no progression group [16, 22].  
 
Identification and validation of VTE 
All incident VTE events during follow-up were identified by searching the hospital 
discharge diagnosis registry, the autopsy registry and the radiology procedure registry at 
the University Hospital of North Norway. The University Hospital of North Norway is 
the only hospital in the region, and all diagnostic radiology and hospital care is provided 
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exclusively by this hospital. The medical record for each potential case of VTE was 
reviewed by trained personnel, and a VTE event was considered adjudicated when 
presence of clinical signs and symptoms of DVT or PE were combined with objective 
confirmation tests (by compression ultrasonography, venography, spiral computed 
tomography, perfusion-ventilation scan, pulmonary angiography, autopsy), and resulted 
in a VTE diagnosis that required treatment, as previously described in detail [23]. DVTs 
were recorded in the upper and lower extremities including inferior vena cava, and at 
unusual sites (the mesenteric veins, portal veins, and in the venous sinuses). VTE cases 
from the autopsy registry were recorded when the death certificate indicated VTE as 
cause of death or a significant condition contributing to death.  
 
Statistical analysis  
Statistical analyses were performed with STATA version 14.0 (Stata Corporation, 
College Station, TX, USA). As the distribution of TPA was skewed to the right, TPA was 
square root transformed to approximate normal distribution for the analyses in which 
TPA was used as a continuous variable. Cox proportional hazard regression models were 
used to assess the association between atherosclerosis (i.e. TPA and IMT) and VTE in a 
time-varying analysis. In these analyses, all participants contributed with one or more 
observation periods, each lasting from one measurement until the next, or until a 
censoring event (i.e. migration, death or end of study period) occurred. The follow-up 
ended on December 31, 2012. Atherosclerosis measurements and other risk factors were 
updated at every survey, when available, and used as time-varying covariates. Of the 
10426 participants included in the study, 5154 participants attended two or three surveys, 
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which resulted in a total number of 18154 observation periods for the time-varying 
analyses. For participants attending only one survey, measurements were valid from 
baseline to the first censoring event. Age was used as time-scale, with the participants’ 
age at study enrolment defined as entry-time and age at the censoring event as exit-time. 
Hazard ratios (HRs) with 95% confidence intervals (CI) were calculated, and all analyses 
were adjusted for age (as time-scale), sex and BMI. The proportional hazards assumption 
was confirmed by the Schoenfeld’s global test. Statistical interactions between the 
covariates and the main exposures were tested by including the cross-product terms in the 
proportional hazard model, and no interactions were found. 
We performed two sensitivity analyses. In the first sensitivity analysis we 
censored participants at the next survey they did not attend. This analysis was 
performed to ensure that the carry-on of measurements in participants who only 
attended one survey did not dilute the effect in the original analyses. Statin use may 
potentially confound the association between atherosclerosis and VTE. Since we did 
not have sufficient information on statin use among the Tromsø 4 participants, the 
second sensitivity analysis was restricted to participants who did not use lipid-lowering 
drugs in Tromsø 5 or Tromsø 6. 
 
Results 
During a median follow-up of 10.8 years, 368 participants experienced an incident VTE 
event. Baseline characteristics of traditional atherosclerotic risk factors and TPA across 
quartiles of carotid IMT are shown in Table 1. In general, all traditional atherosclerotic 
risk factors changed for the worse across increasing quartiles of IMT. Participants in the 
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fourth quartile had higher blood pressure, BMI, triglycerides and total cholesterol, and 
lower HDL cholesterol, compared with participants in the first quartile. Participants in the 
highest quartile also comprised a higher proportion of males as well as participants with 
hypertension and self-reported diabetes, and a lower proportion of physically active and 
highly educated participants. Each quartile of IMT comprised approximately the same 
proportion of current smokers. 
 HRs for VTE by TPA and IMT as continuous and categorical variables are shown 
in Table 2. There was no association between TPA as a continuous variable and VTE 
(HR per standard deviation [SD] increase 0.99, 95% CI 0.90-1.11), and no linear trend of 
increased risk of VTE across increasing tertiles of TPA when no plaque was set as the 
reference group (P for trend=0.9). IMT was not associated with risk of VTE (HR per SD 
increase 0.96, 95% CI 0.86-1.07) and the P for trend across increasing quartiles of IMT 
was 0.7. Additional adjustment for total cholesterol, high-density lipoprotein cholesterol, 
smoking, diabetes mellitus and diastolic blood pressure had a negligible effect on the risk 
estimates (HR per SD increase for TPA and IMT were 0.98 [95% CI 0.88-1.09] and 0.96 
[0.86-1.07], respectively). Similar results were observed when the participants were 
censored at the first survey they did not attend (Supplementary table 1) and when the 
analyses were restricted to participants not using lipid-lowering drugs in Tromsø 5 or 6 
(Supplementary table 2).  
 HR for VTE according to formation and progression of carotid plaques are 
displayed in Table 3. There was no association between plaque formation and future risk 
of VTE (HR 1.00, 95% CI 0.98-1.02). Progression of carotid plaque size was not 
associated with VTE (HR 0.96, 95% CI 0.84-1.11), and there was no linear trend of VTE 
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risk across tertiles of plaque progression in TPA (P for trend=0.5).  The multivariable 
adjusted model showed similar results for both plaque formation and plaque progression. 
 
Discussion 
Previous case-control studies have reported an association between carotid plaques and 
VTE [6, 24], whereas later cohort studies [11-13] have not shown any association 
between carotid atherosclerosis and future risk of VTE. A potential limitation of cohorts 
with long follow-up is that changes in atherosclerosis over time could lead to an 
underestimation of the true association between atherosclerosis and VTE [14, 15]. To 
investigate whether the apparent discrepant results in case-control and cohort studies 
could be explained by regression dilution bias, we conducted a study with repeated 
measurements of carotid atherosclerosis within the same individuals during follow-up. 
We found that measures of carotid atherosclerosis were not associated with future risk of 
VTE. Our findings suggest that atherosclerosis as measured with carotid ultrasound is not 
an intermediate for the association between arterial and venous thrombosis. 
 Our results are in accordance with previous cohort studies on the association 
between atherosclerosis and VTE using time-fixed analyses [11-13]. The Atherosclerosis 
Risk in Communities (ARIC) study, which included 13,000 subjects aged 45-64 years 
with a median follow-up time of 12.5 years, found no association between increased 
carotid IMT or presence of carotid plaques, and VTE risk [11]. The Cardiovascular 
Health Study (CHS) study followed 4100 subjects aged 65 and older over 12 years, and 
measured subclinical atherosclerosis by IMT, presence of carotid plaques, ankle brachial 
index and ECG abnormalities. In this study, subclinical atherosclerosis was not associated 
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with increased risk of overall or unprovoked VTE. Unexpectedly, they found an inverse 
relationship between high-risk carotid plaques and VTE [12]. Furthermore, a previous 
study from the Tromsø cohort with 15.4 years of follow-up, including more than 6200 
participants, found that single measurements of IMT and TPA at baseline were associated 
with future myocardial infarction, but not VTE [13].  
The finding of no association between atherosclerosis and VTE in cohort studies 
is in contrast to the results from two previous case-control studies [6, 24]. Prandoni et al 
reported a higher frequency of carotid plaques in 153 patients with unprovoked VTE 
compared to 146 patients with provoked VTE and 150 hospitalized controls. In this study 
plaques were defined as a protrusion into the vessel lumen of at least 2 mm (6). In a study 
including 89 cases of unprovoked VTE and 89 controls, Hong et al reported an 
association between coronary artery calcification and VTE (22). Several factors may 
explain the diverging results from cohorts and case-control studies conducted on this 
topic. Recruitment of controls that are not fully representative of the source population 
from which the cases were derived, may result in overestimation of the true effect in 
case-control studies. This problem is more likely to occur when the size of the control 
group is small. Moreover, the exposure is measured after the outcome in case-control 
studies, and therefore the temporal sequence of the events cannot be determined. In 
conventional cohorts, exposure may change over time and this may lead to 
underestimation of the true effect. However, with repeated measurements it was possible 
to update an individual’s risk status over time, and consequently get a better estimation of 
an individual’s atherosclerosis status in the period before the VTE diagnosis. Using this 
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approach, we did not find any association between carotid atherosclerosis measures and 
VTE risk. 
 Although some studies have reported associations between atherosclerotic risk 
factors such as diabetes, hypertension and dyslipidemia, and risk of VTE [25-27], the 
only atherosclerotic risk factors that have consistently been shown to increase the risk of 
VTE are age and obesity [18, 28, 29]. A recent meta-analysis of 9 cohorts, including 
almost 250,000 participants and 5000 VTEs, found no association between traditional, 
modifiable atherosclerotic risk factors and VTE, using traditional time-fixed Cox 
regression models adjusted for age, sex and BMI [30]. The only exception was cigarette 
smoking, which was associated with increased risk of provoked VTE, an association that 
was possibly mediated through other conditions such as cancer. Furthermore, in a 
previous report from the Tromsø study, based on repeated measurements of 
atherosclerotic risk factors, we showed that BMI, but not blood pressure, serum lipid 
levels, diabetes or smoking, were associated with increased risk of VTE [31].  
Major strengths of our study include the prospective design with repeated 
exposure measurements and long follow-up, the large number of participants recruited 
from the general population, and the thorough validation and adjudication of VTE. The 
repeated measurements of atherosclerosis and potential confounders made it possible to 
update risk status over time, and thereby to reduce the chance of regression dilution bias. 
The study has some limitations. Unfortunately, we did not have verified baseline 
information on previous history of VTE among all the study-subjects. We started to 
identify VTE cases in January 1994, and those who were registered with a recurrent event 
in the study period (1994-2012), and those who had a VTE shortly before inclusion, were 
 14 
identified and excluded from the analyses due to previous VTE. Subjects who had a VTE 
before 1994 and did not experience a recurrence in the study period would not be 
detected, and consequently, these would be treated as healthy participants during follow-
up. As the prevalence of VTE in the general population is relatively low, this would lead 
to only a small change in the overall number of person-years at risk, and thus would 
presumably have a negligible influence on the risk estimates. Carotid ultrasonography is 
operator dependent and prone to measurement errors. However, a previous study found 
the overall reproducibility of TPA to be good, with small inter-observer mean arithmetic 
and mean absolute differences [16]. Although the measurement errors in carotid 
ultrasonography are too big to study progression of atherosclerosis at an individual level, 
carotid ultrasonography at a population level gives enough power to overcome the 
measurement variability, and makes it possible to detect even weak associations [16]. 
Examination of only one carotid artery may potentially introduce misclassification. 
However, studies comparing ultrasound IMT measurements of the left and right common 
carotid artery found no significant difference between the sides in the normal population 
[32, 33]. Furthermore, studies have shown that carotid atherosclerosis correlates well 
with the general extent of atherosclerotic disease in an individual [34, 35]. Statins has 
been shown to reduce the risk of VTE in some [36-38], but not all studies [39, 40]. Statin 
use reduces carotid plaque development and lowers plaque progression [41, 42], and lack 
of adjustment for statin use could result in underestimation of the association between 
atherosclerosis and VTE. However, sensitivity analysis restricted to participants who did 
not use statins showed no association between carotid atherosclerosis and VTE. Aspirin is 
often prescribed to subjects at risk of cardiovascular disease, but may also prevent venous 
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thrombosis. However, although aspirin use has been associated with decreased risk of 
recurrent VTE [43, 44], it has not been associated with reduced risk of incident VTE in 
population based studies [37, 45].  
In conclusion, we found that formation and progression of carotid atherosclerosis, 
as measured with ultrasound, was not associated with future risk of VTE in time-varying 
analyses. Our findings suggest that atherosclerosis is not an intermediate for the 
association between arterial cardiovascular diseases and VTE. 
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Table 1. Baseline characteristics of traditional atherosclerotic risk factors across quartiles 
of carotid intima media thickness (IMT). In total, 10426 participants were included in the 
study. The Tromsø Study, 1994-2012.  








Number of participants, n 2612 2618 2590 2606 
VTE events, n 69 92 79 128 
Age, years 53.2 ± 10.4 59.1 ± 6.7 61.5 ± 6.6 64.2 ± 6.7 
Male sex, % 31.9 (832) 39.5 (1034) 51.1 (1323) 59.2 (1542) 
Systolic BP, mmHg 131 ± 19 139 ± 21 144 ± 22 152 ± 23 
Diastolic BP, mmHg 78 ± 11 81 ± 12 83 ± 12 85 ± 13 
Hypertension, %* 34.0 (887) 50.9 (1331) 62.9 (1626) 75.1 (1956) 
BMI, kg/m2 25.2 ± 3.7 26.4 ± 4.1 26.8 ± 4.0 27.2 ± 4.2 
Triglycerides, mmol/L 1.47 ± 0.98 1.61 ± 0.99 1.67 ± 1.01 1.80 ± 1.02 
Total cholesterol, mmol/L 6.19 ± 1.23 6.40 ± 1.26 6.43 ± 1.27 6.61 ± 1.35 
HDL cholesterol, mmol/L 1.61 ± 0.45 1.59 ± 0.44 1.53 ± 0.42 1.46 ± 0.43 
Self-reported diabetes, % 1.6 (42) 2.8 (72) 3.7 (95) 6.0 (155) 
Smoking, % 31.6 (823) 26.9 (703) 27.0 (699) 29.2 (761) 
Physical activity, % † 32.8 (817) 33.9 (844) 31.6 (776) 25.6 (632) 
Education, % ‡ 26.1 (653) 23.8 (584) 21.7 (522) 17.4 (426) 
Total plaque area, mm2  0.55 ± 1.29 1.18 ± 1.79 1.98 ± 2.23 3.97 ± 2.68 
No plaque, %  82.8 (2163) 65.9 (1725) 50.5 (1307) 21.9 (570) 
1st tertile, %  10.7 (280) 18.2 (476) 18.1 (468) 12.7 (330) 
2nd tertile, % 4.8 (126) 10.8 (282) 18.8 (488) 25.2 (658) 
3rd tertile, % 1.7 (43) 5.1 (135) 12.6 (327) 40.2 (1048) 
Values are % (n) or mean ± SD. BP indicates blood pressure; BMI, body mass index; 
HDL, high-density lipoprotein. 
* Hypertension: systolic BP ≥140 or diastolic BP ≥90 or use of antihypertensive medicine 
† Hard physical activity 1 hour or more every week 
‡Over/equal to 15 years of education (corresponding to 3 years in university or academy) 
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Table 2. Hazard ratios (HR) with 95% confidence intervals (CI) of venous 
thromboembolism (VTE) according to total plaque area and intima media thickness using 
a time-varying Cox regression model. The Tromsø Study 1994-2012. 
Risk factors Events Person-years HR (95% CI) † 
Total Plaque Area* 368  0.99 (0.90-1.11) 
No plaque 140 54062 Ref. 
1st tertile (1.018-3.506 mm2) 64 19648 0.93 (0.69-1.29) 
2nd tertile (3.506-5.031 mm2) 78 19141 1.04 (0.79-1.38) 
3rd tertile (5.031-15.696 mm2) 86 18685 1.00 (0.75-1.32) 
P for trend   0.9 
Intima Media Thickness* 368  0.96 (0.86-1.07) 
1st quartile (0.358-0.743 mm) 58 29229 Ref. 
2nd quartile (0.744-0.849 mm) 81 28210 0.95 (0.68-1.34) 
3rd quartile (0.849-0.970 mm) 101 27201 1.02 (0.73-1.43) 
4th quartile (0.971-2.748 mm) 128 26896 1.07 (0.77-1.50) 
P for trend   0.5 
* Per standard deviation (SD) increase; 1 SD TPA = 2.60 mm2; 1 SD IMT = 0.19 mm 

















Table 3. Hazard ratios (HR) with 95% confidence intervals (CI) for venous 
thromboembolism (VTE) by initiation and progression of carotid plaques. The Tromsø 
Study 1994-2012. 
 Model 1 
 HR (95% CI) § 
Model 2 
 HR (95% CI) ¶  
Plaque formation* 1.00 (0.98-1.02) 1.00 (0.98-1.02) 
Plaque progression† 0.96 (0.84-1.11) 0.96 (0.83-1.11) 
No progression‡ Ref. Ref. 
0.010-8.250 mm2 increase 0.85 (0.42-1.01) 0.68 (0.44-1.05) 
8.254-17.8401 mm2 increase 0.99 (0.68-1.44) 1.00 (0.68-1.46) 
17.850-131.734 mm2 increase 0.85 (0.57-1.25) 0.84 (0.56-1.25) 
P for trend 0.5 0.5 
* Initiation of plaque, i.e. increase from 0. Based on TPA measurement 
† 1 standard deviation (SD) change in plaque size based on TPA measurement. 1 SD = 
13.2 mm2 increase 
‡ Participants with negative change were included in the no progression group. 
§ Adjusted for age (as time scale), sex and BMI 
¶ Adjusted for age (as time scale), sex, BMI, total cholesterol, high-density lipoprotein 















Figure 1. Study population. Study population recruited from the second visit at the 
fourth, fifth and sixth surveys of The Tromsø Study, conducted in 1994-95, 2001-02 and 
2007-08, respectively.  
 
